Peter Pfreundschuh

2018

In 2018, Peter Pfreundschuh earned a total compensation of $2.5M as Chief Financial Officer at UroGen Pharma Ltd..

Compensation breakdown

Non-Equity Incentive Plan$96,800
Option Awards$1,704,505
Salary$156,424
Stock Awards$527,875
Other$197
Total$2,485,800

Pfreundschuh received $1.7M in option awards, accounting for 69% of the total pay in 2018.

Pfreundschuh also received $96.8K in non-equity incentive plan, $156.4K in salary, $527.9K in stock awards and $197 in other compensation.

Rankings

In 2018, Peter Pfreundschuh's compensation ranked 4,697th out of 14,244 executives tracked by ExecPay. In other words, Pfreundschuh earned more than 67.0% of executives.

ClassificationRankingPercentile
All
4,697
out of 14,244
67th
Division
Manufacturing
1,767
out of 5,765
69th
Major group
Chemicals And Allied Products
639
out of 2,128
70th
Industry group
Drugs
537
out of 1,817
70th
Industry
Pharmaceutical Preparations
414
out of 1,391
70th
Source: SEC filing on April 26, 2019.

Pfreundschuh's colleagues

We found six more compensation records of executives who worked with Peter Pfreundschuh at UroGen Pharma Ltd. in 2018.

2018

Ron Bentsur

UroGen Pharma Ltd.

Chief Executive Officer

2018

Stephen Mullennix

UroGen Pharma Ltd.

Chief Financial Officer

2018

Gil Hakim

UroGen Pharma Ltd.

Former President

2018

Gary Titus

UroGen Pharma Ltd.

Chief Financial Officer

2018

Peter Pfreundschuh

UroGen Pharma Ltd.

Chief Financial Officer

2018

Mark Schoenberg

UroGen Pharma Ltd.

Chief Medical Officer

News

In-depth

You may also like